Recent News

• 03.24.2025 - Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
• 03.24.2025 - Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
• 03.17.2025 - 37th Annual Roth Conference
• 03.17.2025 - 37th Annual Roth Conference
• 02.27.2025 - Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
• 02.27.2025 - Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
• 02.24.2025 - Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
• 02.24.2025 - Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Recent Filings

• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.17.2025 - 144 Report of proposed sale of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.27.2025 - EX-99.1 EX-99.1
• 02.27.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 02.27.2025 - 8-K Current report